63 related articles for article (PubMed ID: 17889397)
1. 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease.
Pertuit D; Moulari B; Betz T; Nadaradjane A; Neumann D; Ismaïli L; Refouvelet B; Pellequer Y; Lamprecht A
J Control Release; 2007 Nov; 123(3):211-8. PubMed ID: 17889397
[TBL] [Abstract][Full Text] [Related]
2. Active nanoparticle targeting of MUC5AC ameliorates therapeutic outcome in experimental colitis.
Riemann B; Antoine T; Béduneau A; Pellequer Y; Lamprecht A; Moulari B
Nanoscale; 2024 Mar; 16(11):5715-5728. PubMed ID: 38407269
[TBL] [Abstract][Full Text] [Related]
3. A Spatially Stable Crystal-Particle Gel to Trap Patchouli Oil for Efficient Colonic Drug Delivery.
Guo R; Xu W; Wang Y; Yue L; Huang S; Xiu Y; Huang Y; Wang B
ACS Appl Mater Interfaces; 2024 Jun; 16(22):29198-29209. PubMed ID: 38785397
[TBL] [Abstract][Full Text] [Related]
4. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease.
Beloqui A; Coco R; Memvanga PB; Ucakar B; des Rieux A; Préat V
Int J Pharm; 2014 Oct; 473(1-2):203-12. PubMed ID: 25014369
[TBL] [Abstract][Full Text] [Related]
5. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease.
Lautenschläger C; Schmidt C; Lehr CM; Fischer D; Stallmach A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):578-86. PubMed ID: 24084650
[TBL] [Abstract][Full Text] [Related]
6. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.
Xiao B; Xu Z; Viennois E; Zhang Y; Zhang Z; Zhang M; Han MK; Kang Y; Merlin D
Mol Ther; 2017 Jul; 25(7):1628-1640. PubMed ID: 28143741
[TBL] [Abstract][Full Text] [Related]
7. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies.
Coco R; Plapied L; Pourcelle V; Jérôme C; Brayden DJ; Schneider YJ; Préat V
Int J Pharm; 2013 Jan; 440(1):3-12. PubMed ID: 22820482
[TBL] [Abstract][Full Text] [Related]
8. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.
Laroui H; Dalmasso G; Nguyen HT; Yan Y; Sitaraman SV; Merlin D
Gastroenterology; 2010 Mar; 138(3):843-53.e1-2. PubMed ID: 19909746
[TBL] [Abstract][Full Text] [Related]
9. Anti-Inflammatory Activity of Chitosan and 5-Amino Salicylic Acid Combinations in Experimental Colitis.
Jhundoo HD; Siefen T; Liang A; Schmidt C; Lokhnauth J; Béduneau A; Pellequer Y; Larsen CC; Lamprecht A
Pharmaceutics; 2020 Oct; 12(11):. PubMed ID: 33138176
[TBL] [Abstract][Full Text] [Related]
10. Mesalazine-PAMAM Nanoparticles for Transporter-Independent Intracellular Drug Delivery: Cellular Uptake and Anti-Inflammatory Activity.
Gorzkiewicz M; Marcinkowska M; Studzian M; Karwaciak I; Pulaski L; Klajnert-Maculewicz B
Int J Nanomedicine; 2023; 18():2109-2126. PubMed ID: 37122501
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting.
Ries M; Moulari B; Shetab Boushehri MA; Ali ME; Molnar D; Béduneau A; Pellequer Y; Lamprecht A
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214083
[TBL] [Abstract][Full Text] [Related]
12. Oral Delivery of Encapsulated All-Trans Retinoic Acid Ameliorates Disease in Rodent Models of Colitis.
Nicoletti F; Hammer L; Furtado S; Mangano K; Mathiowitz E; Green B; Auci DL
Inflamm Bowel Dis; 2022 Mar; 28(3):455-465. PubMed ID: 34417826
[TBL] [Abstract][Full Text] [Related]
13. Gut Organoid as a New Platform to Study Alginate and Chitosan Mediated PLGA Nanoparticles for Drug Delivery.
Davoudi Z; Peroutka-Bigus N; Bellaire B; Jergens A; Wannemuehler M; Wang Q
Mar Drugs; 2021 May; 19(5):. PubMed ID: 34065505
[TBL] [Abstract][Full Text] [Related]
14. Oral encapsulated transforming growth factor β1 reduces endogenous levels: Effect on inflammatory bowel disease.
Hammer L; Furtado S; Mathiowitz E; Auci DL
World J Gastrointest Pharmacol Ther; 2020 Nov; 11(5):79-92. PubMed ID: 33251033
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease.
Zhang S; Langer R; Traverso G
Nano Today; 2017 Oct; 16():82-96. PubMed ID: 31186671
[TBL] [Abstract][Full Text] [Related]
16. Intestinal organoids containing poly(lactic-co-glycolic acid) nanoparticles for the treatment of inflammatory bowel diseases.
Davoudi Z; Peroutka-Bigus N; Bellaire B; Wannemuehler M; Barrett TA; Narasimhan B; Wang Q
J Biomed Mater Res A; 2018 Apr; 106(4):876-886. PubMed ID: 29226615
[TBL] [Abstract][Full Text] [Related]
17. Bioengineering Bacterially Derived Immunomodulants: A Therapeutic Approach to Inflammatory Bowel Disease.
Herrera Estrada L; Wu H; Ling K; Zhang G; Sumagin R; Parkos CA; Jones RM; Champion JA; Neish AS
ACS Nano; 2017 Oct; 11(10):9650-9662. PubMed ID: 28872828
[TBL] [Abstract][Full Text] [Related]
18. Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases.
Prosperi D; Colombo M; Zanoni I; Granucci F
Semin Immunol; 2017 Dec; 34():61-67. PubMed ID: 28855088
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticle-based delivery enhances anti-inflammatory effect of low molecular weight heparin in experimental ulcerative colitis.
Yazeji T; Moulari B; Beduneau A; Stein V; Dietrich D; Pellequer Y; Lamprecht A
Drug Deliv; 2017 Nov; 24(1):811-817. PubMed ID: 28509629
[TBL] [Abstract][Full Text] [Related]
20. 5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice.
Tang H; Xiang D; Wang F; Mao J; Tan X; Wang Y
Mol Med Rep; 2017 Mar; 15(3):1117-1122. PubMed ID: 28138699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
